Evolocumab lowers mortality in patients at high CV risk without prior MI or stroke

ESC Congress 2026 – In a prespecified analysis of VESALIUS-CV, evolocumab was associated with a 20% lower rate of all-cause mortality compared with placebo in high-risk patients without a previous MI or stroke. The mortality benefit emerged after approximately 1.5 years of treatment.
This summary is based on the presentation of Robert Giugliano, MD (Boston, MA, USA) at the ESC Congress 2026 - Effects of Evolocumab on Fatal Outcomes in Patients Without a Prior Myocardial Infarction or Stroke: Pre-specified Analysis of the VESALIUS-CV Trial.
Introduction and methods
In the VESALIUS-CV trial, the PCSK9 inhibitor evolocumab reduced the risk of MACE in high-risk patients without a previous MI or stroke. In this prespecified analysis of VESALIUS-CV, the investigators assessed the effects of evolocumab on all-cause and cause-specific mortality.
VESALIUS-CV was a double-blind, randomized trial that included 12,257 stable patients at high-risk for CV events, without a previous MI or stroke. Patients had coronary artery disease with no MI, cerebrovascular disease with no stroke, peripheral artery disease, or high-risk diabetes. Eligible patients had LDL-c ≥90 mg/dL, non-HDL-c ≥120 mg/dL or apolipoprotein B ≥80 mg/dL on optimized statin therapy with or without ezetimibe. Participants were randomized to subcutaneous evolocumab 140 mg every 2 weeks or placebo.
Prespecified mortality outcomes included all-cause mortality, CV mortality, non-CV mortality and death from an undetermined cause.
Main results
- Evolocumab was associated with a lower rate of all-cause mortality compared with placebo:
- Evolocumab: 434 deaths; 5-year Kaplan–Meier rate: 7.9%.
- Placebo: 539 deaths; 5-year Kaplan–Meier rate: 9.7%.
- HR: 0.80; 95%CI: 0.70–0.91; nominal P=0.0005.
- There was no difference in all-cause mortality during the first 1.5 years (HR: 0.99; 95%CI: 0.78–1.25). After 1.5 years, evolocumab was associated with a 27% lower rate of all-cause mortality (HR: 0.73; 95%CI: 0.63–0.85).
- The effect of evolocumab on all-cause mortality was consistent across key subgroups, including age, sex, qualifying disease category, baseline LDL-c concentration, statin intensity or ezetimibe use (all P for interaction>0.16).
- Lower rates of all-cause mortality with evolocumab were observed both in patients with qualifying atherosclerosis (HR: 0.84; 95%CI: 0.72–0.98) and in those with high-risk diabetes without qualifying atherosclerosis (HR: 0.74; 95%CI: 0.60–0.91; P for interaction=0.34).
- Results consistently favored evolocumab versus placebo across the major categories of death: CV mortality (156 vs. 195 deaths; HR: 0.79; 95%CI: 0.64–0.98), non-CV mortality (229 vs. 268 deaths; HR: 0.85; 95%CI: 0.71–1.01) and death from an undetermined cause (49 vs. 76 deaths; HR: 0.64; 95%CI: 0.45–0.92).
- Multistate modeling suggested that approximately 78% of the observed effect of evolocumab on non-CV mortality could be explained by the prevention of preceding nonfatal CV events.
Conclusion
In this prespecified analysis of VESALIUS-CV, evolocumab was associated with a lower rate of all-cause mortality in high-risk patients without a previous MI or stroke. The survival benefit emerged after approximately 1.5 years and was consistent in patients with qualifying atherosclerosis and those with high-risk diabetes without qualifying atherosclerosis.
- Our reporting is based on the information provided at the ESC Congress 2026 -
